Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis
CLDX•Phase 2 study results and program updates
- Celldex Therapeutics Inc. reported results from its Phase 2 study of barzolvolimab in prurigo nodularis.
- The Phase 2 study of barzolvolimab in prurigo nodularis did not meet key efficacy objectives.
- Celldex Therapeutics said it discontinues the Phase 2 study of barzolvolimab in prurigo nodularis.
- The company said barzolvolimab was well tolerated, with a favorable safety profile consistent with prior studies, including with the new 450mg loading dose and up to 300mg q4w regimen.
- Celldex Therapeutics said profound systemic mast cell depletion was observed in the Phase 2 study.
- Phase 3 CSU topline data are expected in Sept./Oct. 2026, and Phase 3 SD and cold urticaria enrollment is on track.
